Bruker
BRUKER CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.4B
Operating marginCalculated
2.0%
Net assets to total assetsCalculated
39.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
2.0%
Growth (revenue, 4-year average)
★★★★☆position among all companies
9.2%
Capital efficiency
★☆☆☆☆position among all companies
-0.4%
Revenue and profit
Performance, financial position and capital allocation
Bruker
Recent performance trends
Bruker
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$2.4 billion | US$2.5 billion | US$3.0 billion | US$3.4 billion | US$3.4 billion |
| Operating income | US$0.4 billion | US$0.4 billion | US$0.4 billion | US$0.3 billion | US$68.20 million |
| Net income | US$0.3 billion | US$0.3 billion | US$0.4 billion | US$0.1 billion | US$-8.60 million |
| Total assets | US$3.6 billion | US$3.6 billion | US$4.2 billion | US$5.8 billion | US$6.2 billion |
| Shareholders' equity | US$1.1 billion | US$1.1 billion | US$1.4 billion | US$1.8 billion | US$2.5 billion |
| Net cash provided by (used in) operating activities | US$0.3 billion | US$0.3 billion | US$0.4 billion | US$0.3 billion | US$0.1 billion |
| Net cash provided by (used in) investing activities | US$-0.2 billion | US$-0.3 billion | US$-0.3 billion | US$-1.8 billion | US$-0.2 billion |
| Net cash provided by (used in) financing activities | US$0.3 billion | US$-0.4 billion | US$-0.2 billion | US$1.2 billion | US$0.1 billion |
| Cash and cash equivalents | US$1.1 billion | US$0.6 billion | US$0.5 billion | US$0.2 billion | US$0.3 billion |
Revenue scale in the same industry
Bruker
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 34 companies
- 38 Leonardo DRSFY Dec 2025 US$3.6B
- 39 TrimbleFY Jan 2026 US$3.6B
- 40 BrukerThis companyFY Dec 2025 US$3.4B
- 41 TeradyneFY Dec 2025 US$3.2B
- 42 WatersFY Dec 2025 US$3.2B
- … 1 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$90.80 million | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Dividends paid | US$22.80 million | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$2.5 billion | Consolidated | Disclosed |
| Non-controlling interests | US$17.00 million | Consolidated | Disclosed |
| Net assets | US$2.5 billion | Consolidated | Disclosed |
| Net sales | US$3.4 billion | Consolidated | Disclosed |
| Operating income | US$68.20 million | Consolidated | Disclosed |
| Net income | US$-8.60 million | Consolidated | Disclosed |
| Total assets | US$6.2 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$10.00 million | Consolidated | Disclosed |
| Operating margin | 2.0% | Consolidated | Calculated |
| Net assets to total assets | 39.4% | Consolidated | Calculated |
| Net margin | -0.3% | Consolidated | Calculated |
| Return on equity | -0.4% | Consolidated | Calculated |